Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : XS411
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
XellSmart's iPSC Cell Therapies for Parkinson’s and ALS Approved for Phase I
Details : XS411 is an universal allogeneic off-the-shelf iPS-derived dopaminergic neural progenitor cell therapy being developed for the treatment of Parkinson's disease (PD).
Product Name : XS411
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 15, 2025
Lead Product(s) : XS411
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable